IDO1 and neoplasm: IDO1 activity suppresses T-cell activity by depleting tryptophan, which is required for Th1 and CD8+ T-cell-mediated immunity, while kynurenine binds to the aryl hydrocarbon receptor (AHR), which directly activates Treg differentiation and activity, resulting in reduced anti-tumor responses (116–118).